Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267


Real-time Estimate Quote. Real-time Estimate Cboe Europe - 12/06 04:30:07 am
73.88 CHF   +0.42%
12/03Bryan Garnier Downgrades Novartis to Neutral from Buy
12/03NOVARTIS AG : UBS reaffirms its Neutral rating
12/03NOVARTIS AG : Sell rating from JP Morgan
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : Novartis: Sandoz completes acquisition of GSK's cephalosporin business, reinforcing leading global position in antibiotics

10/11/2021 | 03:17am EST
   -- Sandoz gains rights to three established brands sold in more than 100 
   -- Transaction, including leading global brand Zinnat(R), complements Sandoz 
      leadership in generic penicillins with leading position in cephalosporins 
   -- Acquisition confirms Sandoz commitment to antibiotics, following 
      announcement of further investment plans for European-based manufacturing 

Basel, October 11, 2021 -- Sandoz, a Novartis division, has successfully completed the acquisition of GSK's cephalosporin antibiotics business.

Through this transaction, Sandoz has acquired rights to three established brands (Zinnat, Zinacef and Fortum() ) in more than 100 markets, further reinforcing its leading global position in antibiotics. In 2020, the three brands had combined sales of approximately USD 140 million in the relevant markets.

"Antibiotics are the backbone of modern healthcare systems and a central pillar of our worldwide Sandoz patient offering", said Sandoz CEO Richard Saynor. "The successful and timely closing of this important transaction is further proof of our commitment at Sandoz to be a leading global supplier of these essential medicines.

"Cephalosporins are the largest antibiotic segment by global sales and this acquisition complements our #1 position in generic penicillins, the other key segment. It also sets us up for additional synergies driven by an increased promotional footprint across markets."

The transaction excludes rights to certain brands previously divested by GSK in the US, Australia and Germany. GSK will also retain full brand rights in China (excluding Taiwan, Hong Kong and Macau), India, Pakistan, and Egypt and to certain brands in Japan.

In line with its integrated manufacturing strategy, Sandoz intends in the longer term to manufacture Zinnat at sites in its own network, which has global antibiotics production centered on its lead production site in Kundl, Austria. In May, Sandoz announced plans to invest more than EUR 150 million in its uniquely vertically-integrated, European-based antibiotics network.


This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plans," "commitment," "to acquire," "to expand," "expected," "intends," "expect," "focus," "complements," "leading," or similar terms, or by express or implied discussions regarding the agreement to acquire GSK's cephalosporin antibiotics business; or regarding potential future revenues from Zinnat, Zinacef or Fortum. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the expected benefits or synergies from the transaction described in this press release will be achived in the expected timeframe, or at all. Neither is there any guarantee that Zinnat, Zinacef or Fortum will be commercially successful in the future. In particular, our expectations regarding the transaction described in this press release and Zinnat, Zinacef and Fortum could be affected by, among other things, regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sandoz

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world's leading and most valued generics company. Our broad portfolio of high-quality medicines, covering major therapeutic areas, accounted for 2020 sales of USD 9.6 billion.

Sandoz on social media:

LinkedIn: https://www.linkedin.com/company/sandoz/

Twitter: https://twitter.com/sandoz_global

Facebook: https://www.facebook.com/sandozglobal/

Instagram: https://www.instagram.com/sandozglobal https://www.instagram.com/sandozglobal

CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/

Novartis and Sandoz Global Communications

E-mail : media.relations@novartis.com

Richard Jarvis                   Chris Lewis 
 Novartis Global Communications   Sandoz Global Communications 
 +41 79 584 23 26 (mobile)        +49 174 244 9501 (mobile) 
 richard.jarvis@novartis.com      chris.lewis@sandoz.com 

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central                                      North America 
Samir Shah              +41 61 324 7944      Sloan Simpson  +1 862 778 5052 
Thomas Hungerbuehler   +41 61 324 8425 
 Isabella Zinck         +41 61 324 7188 

(END) Dow Jones Newswires

October 11, 2021 03:16 ET (07:16 GMT)

All news about NOVARTIS AG
12/03Bryan Garnier Downgrades Novartis to Neutral from Buy
12/03NOVARTIS AG : UBS reaffirms its Neutral rating
12/03NOVARTIS AG : Sell rating from JP Morgan
12/03Drugmakers cut prices by 62% on average to get China state insurance listing
12/02Novartis Mulls Bolt-On Acquisitions
12/02GLOBAL MARKETS LIVE : Hermès, Walt Disney, Apple, Novartis, Square...
12/02MarketScreener's World Press Review - December 2, 2021
12/02Novartis Sees 4% Compound Annual Growth in Sales Through 2026
12/02EUROPEAN MIDDAY BRIEFING - Stocks Tumble Again in -2-
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2021 52 117 M - -
Net income 2021 15 146 M - -
Net Debt 2021 20 532 M - -
P/E ratio 2021 12,6x
Yield 2021 4,10%
Capitalization 179 B 179 B -
EV / Sales 2021 3,83x
EV / Sales 2022 3,62x
Nbr of Employees 108 000
Free-Float 85,7%
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 80,15 $
Average target price 97,47 $
Spread / Average Target 21,6%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-12.05%179 058
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010